Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

<p>Table S2</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Yun-Guang Hong (14960966) (author)
Diğer Yazarlar:	Zhigang Yang (14960969) (author), Yan Chen (14960972) (author), Tian Liu (14960975) (author), Yuyuan Zheng (14960978) (author), Chun Zhou (14960981) (author), Guo-Cai Wu (14960984) (author), Yinhui Chen (14960987) (author), Juan Xia (14960990) (author), Ruiting Wen (14960993) (author), Wenxin Liu (14960996) (author), Yi Zhao (14960999) (author), Jin Chen (14961002) (author), Xiangwei Gao (14961005) (author), Zhanghui Chen (14961008) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Yazar:: Yun-Guang Hong (14960966)
Baskı/Yayın Bilgisi: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Yazar:: Yun-Guang Hong (14960966)
Baskı/Yayın Bilgisi: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Yazar:: Yun-Guang Hong (14960966)
Baskı/Yayın Bilgisi: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Yazar:: Yun-Guang Hong (14960966)
Baskı/Yayın Bilgisi: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Yazar:: Yun-Guang Hong (14960966)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Yazar:: Amir T. Fathi (15313195)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Yazar:: Amir T. Fathi (15313195)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Yazar:: Ana Vujovic (15207479)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
Yazar:: Smruthy Sivakumar (15053536)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables from Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib
Yazar:: Xiangyu Zeng (17314920)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Yazar:: Zev A. Wainberg (15047031)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
Yazar:: Jeffrey D. Mandell (14963909)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Yazar:: Yufang Bao (15386826)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Yazar:: Yufang Bao (15386826)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Yazar:: Yufang Bao (15386826)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ttsp0drq1ang0c3vitetrfmrqo